AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 64 min read$HAE

HAEMONETICS CORP (HAE): Results of Operations and Financial Condition

HAEMONETICS CORP (HAE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991-fy27q1earningsrelease.htm EX-99.1 Document Exhibit 99.1 Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Global Communications (781) 356-9763 (781) 356-9776 olga.guyette@haemonetics.com josh.git

Original reporting
SEC EDGAR 8-K
Published Aug 6, 2026, 10:07 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 10:35 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$HAE
Bullish
high confidence
Mentioned
$HAE
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$HAEBullishHigh
01

Why it matters

The key tradable items are the raised FY2027 GAAP revenue and organic revenue growth ranges, alongside Q1 operating performance (revenue growth, adjusted EPS, cash flow) and margin/tax dynamics that could influence estimate revisions.

02

Market read

Traders can update FY2027 revenue, organic growth, and EPS expectations immediately based on the raised guidance ranges and Q1 cash flow performance.

03

What to watch

Effective tax rate rose due to stock compensation shortfalls and valuation allowance impacts in recently acquired jurisdictions, which may not normalize quickly.

Relevance 7/10Novelty 9/10Timing: pre-market filing today, guidance raise for FY2027

Background

This is Haemonetics’ SEC 8-K with Exhibit 99.1 covering first-quarter fiscal 2027 results (ended June 27, 2026) and updated FY2027 guidance.

Company-level read

Ticker impact

$HAEBullishHigh confidence
Context

Haemonetics reported first-quarter fiscal 2027 results and raised full-year GAAP revenue and organic growth guidance.

Expected impact

Likely positive bias for HAE as traders reprice FY growth and margin trajectory; watch for follow-through versus any tax-margin noise.

Evidence & confidence

The filing includes specific Q1 datapoints (revenue, adjusted EPS, cash flow) and explicit upward guidance ranges for FY2027, which are direct inputs to valuation and estimates.

Market effects

Sector

Medical technology and blood management peers may see modest read-across on demand durability and margin execution.

Regional

Primarily US-listed sentiment; limited direct regional spillover beyond healthcare medtech.

Global

Global medtech investors may adjust expectations for plasma and med-surg growth, but impact is company-specific.

Counterpoint

What could challenge this read

Tax rate volatility and adjusted margin compression drivers could offset the headline guidance raise if they persist.

Key entities

  • issuer
    Haemonetics Corporation

    NYSE-listed medical technology company reporting Q1 fiscal 2027 results and raising FY2027 guidance.

  • executive
    Chris Simon

    CEO quoted on portfolio momentum and disciplined execution supporting the guidance raise.

Read at source← All news

Related articles

AUG 9
$HAEMedAI 8/10

Haemonetics Q1 Earnings Call Highlights

Haemonetics (NYSE:HAE) reported Q1 interventional technologies returning to 3% organic growth, with vascular closure led by VASCADE MVP and MVP XL momentum in the U.S. Apheresis revenue rose 6% organically to $191M and plasma revenue grew 8% organically as Persona PLUS rollout accelerates. Haemonetics raised FY2027 revenue guidance to 5% to 8% reported and 4% to 7% organic.

yahoo.com6 min
AUG 6
$HAEMed

Haemonetics (NYSE:HAE) Beats Q2 CY2026 Sales Expectations

Haemonetics (NYSE:HAE) reported Q2 CY2026 results. Revenue rose 5.6% year on year to $339.4 million, exceeding Wall Street estimates by 2.8%. Non-GAAP adjusted EPS was $1.14, up from $1.10 and 5.8% above consensus. Analysts expect revenue growth of about 5% over the next 12 months and full-year EPS to rise from $5.01 to $5.36.

financialcontent.com6 min
AUG 9
$WATMedAI 8/10

Waters Q2 Earnings Call Highlights

Waters (NYSE:WAT) reported Q2 updates from its earnings call. Materials Science Division revenue rose to $87M. Biosciences and Diagnostic Solutions acquired from BD generated $817M revenue. Waters raised FY organic constant-currency growth outlook to 7% to 9%, projecting FY reported revenue of $3.370B to $3.431B and adjusted EPS of $14.45 to $14.65.

yahoo.com6 min
AUG 9
$VTEXMedAI 8/10

VTEX Q2 Earnings Call Highlights

VTEX (NYSE:VTEX) reported Q2 margin and cash flow improvement and guided for Q3 and full-year low-single-digit FX-neutral subscription revenue growth and low-20% non-GAAP operating and free cash flow margins. Q2 non-GAAP subscription gross margin rose to 81.8%. Free cash flow rose 79% to $12.7M. VTEX repurchased 6.2M shares at $3.76.

yahoo.com6 min
AUG 9
$WMedAI 8/10

Wayfair Q2 Earnings Call Highlights

Wayfair (NYSE:W) said Q2 new-order growth accelerated for a fourth straight quarter to a post-COVID high, citing U.S. gains from pricing, selection, delivery speed and availability, plus initiatives like Wayfair Rewards and stores. Q3 revenue growth is forecast at high-single digits. Perigold sales grew over 35% YoY and exceeded $400M annual. Q2 gross margin was 30.0%, adjusted EBITDA $242M, and free cash flow $301M. The company issued $400M notes to redeem 2028 converts.

yahoo.com6 min
AUG 9
$VYXMed

NCR Voyix Q2 Earnings Call Highlights

NCR Voyix (NYSE:VYX) reported Q2 progress on enterprise platform transformations, including a remote Voyix POS installation for a large European grocery retailer completed in about half the usual time. Retail signed 40+ customers; retail revenue fell 20% to $365M due to hardware transition, but adjusted EBITDA rose 20% to $97M. Restaurant revenue fell 23% to $158M. Non-GAAP EPS was $0.17. Full-year 2026 outlook maintained: revenue $2.188B-$2.303B, adj EBITDA $432M-$447M, EPS $0.89-$0.92.

yahoo.com6 min